Bronwyn has over 20 years executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy. In 2017 she founded ANDHealth, an organisation that supports digital health companies in Australia by providing education, resources, non-dilutive funding and mentorship to help them navigate the complexities of the healthcare industry.

ANDHealth is now one of Australia’s leading health technology commercialisation organisations with companies participating in its flagship ANDHealth+ program raising $19.70 in new capital and generating $6.70 in new revenues for every dollar invested. ANDHealth manages over $30M in public and private commitments to digital health commercialisation, and provides specialist support to a further $100M of funding managed by Brandon Capital.

Bronwyn was a member of the National Health & Medical Research Council for the 2021-2024 Triennium. She is currently a Non-Executive Director of Lumos Diagnostics Ltd (ASX.LDX) alongside a number of other advisory roles.

Liz Ashall-Payne is an accomplished healthcare leader and the Founding CEO of ORCHA, a global leader in digital health accreditation and distribution services. With a background as a trained NHS Clinician, Liz has been at the forefront of healthcare transformation programs in the NHS, Europe, and North America, leveraging the potential of digital technology to enhance patient health outcomes and drive economic opportunities.

In 2015, Liz established ORCHA, a groundbreaking venture. Under Liz's guidance, ORCHA has experienced remarkable growth, expanding its digital health assessment and distribution services to twelve countries worldwide. Within the UK, ORCHA serves organisations in 70% of NHS regions, positioning itself as a trusted partner in the digital health landscape.

Recognised for her exceptional contributions, Liz Ashall-Payne and ORCHA have received numerous accolades. Liz herself has been honoured as a Tech Trailblazer by the BIMA 100, acknowledged as a Healthcare IT Leader in the HIMSS Future 50, and named Entrepreneur of the Year by prestigious institutions such as the British Chamber of Commerce, Norther Powerhouse, and EY. Additionally, she has been featured within the LDC top 50, further highlighting her influential role in the healthcare and technology sectors.

In addition to her accomplishments at ORCHA, Liz Ashall-Payne actively contributes to the development of future healthcare leaders as a coach for the NHS England Clinical Entrepreneur program. Furthermore, Liz serves as a member of Tech Uk board representing SMES and is the Vice Chair on the Tech UK Health and Social Care Council, where she helps shape policies and initiatives in the intersection of technology and healthcare.

Liz is also an honorary lecturer in the school of medicine at UCLAN, and is a research executive at The University of Warwick

Liz Ashall-Payne's visionary leadership, extensive expertise in healthcare transformation, and dedication to harnessing the potential of digital health make her a prominent figure in the industry, driving positive change and innovation for the benefit of patients and healthcare systems worldwide.

Catherine de Fontenay commenced a 5-year term as a full time Commissioner with the Productivity Commission in July 2019.

After completing her PhD in 1998 at Stanford University, Catherine has held faculty positions at the University of New South Wales, then University of Melbourne, with a visiting position at New York University.  Her research on team sin science has been published in Nature Biotechnology.

Catherine leads the Health Productivity stream of research at the PC. She has led work on Measuring Healthcare Productivity, Digital Technologies in Healthcare, Aged Care Employment, and Unpaid Leave for Carers.

Catherine is also currently the President for the Economic Society of Australia.

Professor Shelley Dolan joined the RMH in August2023 as Chief Executive. She is a familiar face in the Parkville Precinct, previously serving as the Chief Executive of the Peter MacCallum Cancer Centre.

In her previous roles, Professor Dolan has successfully led large specialist tertiary hospitals in the UK, including as Chief Executive of KingsCollege Hospital NHS Foundation Trust and Deputy Chief Executive of the RoyalMarsden Hospital.

Professor Dolan is a highly respected clinical and research leader with an impressive track record in health care, having successfully led major organisational and cultural change in Victoria and the United Kingdom (UK).

Key capabilities include executive and non-executive leadership across national and international bodies, strategy development, delivering excellence in quality and performance, overseeing large capital schemes and innovativeresearch projects that require engagement with a broad range of stakeholders.

Professor Shelley Dolan has a PhD in the early diagnosis of sepsis in cancer patients and a master’s degree in advanced practice nursing. She is aProfessor (Enterprise) of the Melbourne School of Health Science at theUniversity of Melbourne.

She is Chair of the Western & Central Melbourne Integrated CancerService, a Board member of the Victorian Comprehensive Cancer Centre Alliance, the Melbourne Academic Centre for Health, Melbourne Genomics and CRCParticipant Director on the Board of Oncology One. In November 2022, theMinister for Health and Aged Care appointed Professor Dolan as a Member of theCancer Australia Advisory Council.

Chris is a founding partner of Brandon Capital and Chief Executive Officer of Brandon BioCatalyst. Chris was previously the Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia.  Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd. Chris has international experience working for the business development group of Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG.

Chris is currently a director of; Azura Ophthalmics, Certa Therapeutics, EBR Systems (ASX:EBR), Global Kinetics Corporation, OccuRx, PolyActiva and Que Oncology. He is also an elected board member of the Australian Investment Council, Chair of CUREator and an advisory board member for The WILD Program.

Chris has a Bachelor of Science (Honours) from The University of Melbourne and a PhD in Endocrinology and Physiology from The University of Melbourne. He studied Private Equity and Venture Capital at Harvard Business School.

Rachel is a partner at Giant Leap. Giant Leap invests in founders solving our most pressing global problems at scale across climate, health and people and has invested in over 30 companies to date.

Rachel is also on the Advisory Board for the Victorian Government’s Equity Investment Attraction Fund and formerly the Chair of the Startup Network, a non-profit, grassroots organisation supporting founders through their startup journey.

She has a background in management consulting and corporate finance, and previously co-founded a non-profit organisation to raise funds and awareness for MotorNeurone Disease

Megan Robertson is the Group Chief Research Officer at St Vincent’s Hospital, Melbourne, and Director of Research at St Vincent’s Hospital Melbourne.

Megan is on the boards of BioMedical Research Victoria, the Caroline Chisolm Centre for HealthEthics and FearLess (PTSD-ANZ), the Bio devices Advisory Board at the ARCTraining Centre in Biodevices at Swinburne University, and the Tuckwell Scholarship Selection Panel at ANU. She also works with national bodies including the Australian Commission on Safety and Quality in Healthcare, AusBioTech, and the National Health and Medical Research Council.

Previously, Megan held positions as the Director of Professional Affairs, CICM, as the ExecutiveDirector of Research at Epworth HealthCare, and as the Co-Director of theIntensive Care Unit at Epworth Freemasons. She is also an alumna of theUniversity of Melbourne where she completed a Bachelor of Medicine, Bachelor ofSurgery (MBBS).

Australian Institute of Company Directors.

Michelle Burke is a Non-Executive Director for Cell Therapies Pty Ltd, AdAlta Pty Ltd, Olivia Newton-John Cancer Research Institute, past Chair of AusBiotech Ltd, and a current member of the Pharmaceutical Benefits Advisory Committee.

She also serves as an advisor for Proto Axiom Pty Ltd, an incubator for early stage research commercialisation.

She is a consultant to health-related companies, governments and academia, and a former director at Bristol-Myers Squibb and SmithKline Beecham.

Olivia holds Bachelors degrees in both Science and Engineering, specialising in molecular biology and mechatronics, alongside a Masters of Applied Cybernetics from the Australian National University.  

Olivia has extensive experience within both the TGA in the regulation of high risk medical devices, and the Digital Transformation Agency with a focus on enabling better digital services delivered by government. She is currently a director in the Medical Devices Authorisation Branch, responsible for the team that assesses the safety and efficacy of medical device software, including those incorporating AI and ML.

‍

Since July 2018, Kate Quirke has been the Group Managing Director andChief Executive Officer of the Alcidion Group, a company dedicated to providingsmart technology to the health sector. Kate leads the business globally with current focus on Australia, NewZealand and the United Kingdom with a goal of developing mutually beneficialrelationships with customers, partners and investors.

Kate has 25+ years of digital health sector experience and has beeninvolved in large procurements and implementations of healthcare informationtechnology across Australia, New Zealand, the United Kingdom and South-East Asia.  Her background includes leadingmanagement roles at large healthcare software firms where she has drivenstrategic product direction.  Shestrongly believes that the astute application of information technology will support the transformation of healthcare delivery worldwide.

Kate was recently appointed as a Non-Executive Director of ANDHealth andpreviously served on the Board of the Stephanie Alexander Kitchen GardenFoundation for 16 years.  During 2021,Kate was recognised as one of Telstra Health’s inaugural Brilliant Women inDigital Health and named Biotech Daily’s CEO of the Year.  In 2020, Kate won the Executive Leader awardin the inaugural B&T Women Leading Tech Awards.  She received her Bachelor of Applied ScienceHealth Information Management degree from Latrobe University.

Peter Chan is an Intensive Care Specialist at Eastern Health, Melbourne. He has recently completed a PhD in the validation of medical devices at Monash University. He is interested in the intersection of technology and patient care in the clinical space. He is currently deputy director of research at Eastern Health ICU services and sits on the Human Research and Ethics Committee. He also sits on a number of advisory boards for healthtech startups and is passionate about finding ways of bringing novel technology to the patients that might benefit from them.

A highly experienced leader in digital health service delivery, Jill is recognised in Australia and internationally for her work in transformative health technology solutions. She is passionate about improving equity and accessibility in the healthcare industry and has extensive experience in leading teams to devise sustainable health innovations.

Jill is committed to building deep connections across the health system to drive the adoption and acceleration of innovative new technologies that deliver more efficient and engaging services.

Clare is a PhD-qualified research scientist with extensive experience in project and stakeholder management and the commercialisation of academic research.

Clare has direct experience in the commercialisation of personalised medicine, bioinformatics and computational biology research projects.

Chris' position is the first of its kind in the faculty. He has more than 30 years' experience in the health industry, including 12 in clinical
medicine.

‍
He's led numerous software development and implementation projects in the health industry and works with many faculties and Institutes across the University, as well as with a range of health industry partners, in leading the Monash efforts in Digital Health.

‍

Dr Arjun Balaji, Investment Associate, TenmileArjun Balaji is a Medical Doctor turned Venture Capitalist, driving innovation at the intersection of healthcare and technology. He practiced at Fiona Stanley Hospital in orthopedics, nephrology, surgery, and emergency medicine. He's also contributed first-author machine learning publications in medicine and has worked at companies like PYC Therapeutics.

At Tenmile he drives investments in AI drug discovery (Verge Genomics), radiopharmaceuticals, and novel vaccines (Limmatech). He also sits on the board of Proxima Bio - a Melbourne based company developing novel protein degraders.

Brandon is an experienced medical entrepreneur having co-founded B2B digital health business,UHG.

He is National Entrepreneurial Lead of Australian Clinical Entrepreneur Program, Director ofHigh Street Medical Clinic, Director of Murdoch Children’s Research Institute and board chair of Victorian Clinical Genetics Service.

Peter Birch is Founder and CEO of Talking HealthTech - a global podcast and membership community originating from Australia, to learn and connect about technology in healthcare.

Pete is a director of the Medical Software Industry Association (MSIA) who are the voice of healthcare software vendors in Australia, and also director of MetaOptima Technology who are helping clinicians diagnose skin cancer using artificial intelligence.

He is also on the NSW State Committee for the Australasia Institute of Digital Health (AIDH), and is a NSW State Facilitator for the Australian Clinical Entrepreneurs Program (AUSCEP).He holds a Master of Business Administration (MBA), is a Certified Health Informatician (CHIA), and also a Certified Practicing Accountant (CPA).

Rob oversees Medibank’s growing role as a health services provider. He is responsible for the health services we deliver on behalf of our health insurance business as well as to customers in the private and public sector. These include prevention programs, telehealth, in-home care, and our healthcare investments across short stay hospitals and primary care. He has been a member of the executive leadership team since November 2023.

Rob joined Medibank in 2022 as Amplar Health’s Chief Commercial Officer, responsible for evolving its health services strategy including our focus on virtual health and growing our prevention services.

Prior to joining Medibank, Rob held senior roles in Private Equity and at leading pharmaceutical company, GSK PLC. Most recently Rob was CEO and Managing Director at MedAdvisor Ltd, a technology-led medication adherence company operating in Australia, US and the UK.

Amish Chaturvediis an experienced market access professional with extensive experience indeveloping and delivering pricing, market access and reimbursement strategies,integrated evidence planning to support HTA. He has worked on Access toMedicine policy across regions and at a country level. In a career spanning 22years he has worked across multiple therapy areas including Oncology, Immunology,Neuroscience, Infectious Diseases and Vaccines. ​

Prior to joining EVERSANA, Amish spent15 years in the industry working as therapy area lead for market access,reimbursement, pricing and policy for Medicines Australia, Abbvie and Janssen(J&J) at a country and regional level. Amish has hands-on experiencemanaging reimbursement submissions to NICE,SMC and AWMSG in the UK. He has adeep understanding of key Asia Pacific markets and their HTA requirements (JP,AU, NZ, SK and TW).

Amish excels in developing marketaccess, pricing and reimbursement strategies, optimizing evidence from a HTAperspective for pipeline assets, shaping policy at therapy area level andinfluencing broader access policies to support launch readiness and HTAsuccess. In addition, Amish helps clients optimize their access andreimbursement strategies at a regional level (EU and APAC) and frame HTAsubmissions at country level.

Amish holds a B-Pharm degree, Masterof Business Administration degree (Australian National University) and HealthEconomics degree from London School of Economics (LSE).

Emily is leading the development of AI in health care policy at the Australian Department of Health and Aged Care.

Originally training as a Physiotherapist, she has held clinical, product development and research, global trade and investment advisory and policy roles with government and industry.

Emily is passionate about creating a policy environment that supports innovation – where digital health technologies can be used safely to equitably improve patient health outcomes for Australians and global citizens.

Scott is an experienced public health executive who joined Red Dust in 2017 following five years as a senior manager at the Stroke Foundation.

Born and raised in North East Arnhem Land Scott is a passionate advocate for working in partnership with remote communities to improve health and wellbeing outcomes.

Adam became a carer after his grandpa was hospitalised following a fall at home. Frustrated by the lack of effective tech solutions available to older adults, he was driven to build his own and founded Umps Health. Today, Umps supports thousands of older adults by providing smart hometechnology alongside traditional care services.

Adam’s background lies at the intersection of technology and public health. One of his earliest roles was at Cochlear China, where he worked with regional governments to make cochlear implantation more accessible to remote communities. Before founding Umps, he worked at Ericsson, developing and deploying digital infrastructure to improve the livability of cities in Australia and Southeast Asia.

In addition to his role at Umps, Adam advises several startups working inaged care and disability. He holds a Master of Public Health, a Bachelor of Commerce, and a Diploma of Languages (Mandarin).

Over his 35 year career Gavin has been a leader and champion of Medical Technology in Australia/NZ and Asia. He has also played lead roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is strong advocate for Gender Equality and Indigenous Engagement.

Gavin is currently CEO of Omnigon, a private Australian company in the Ostomy Care market. He is Chair of ANDHealth (Australia’s National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation. Gavin is a proud member of the Champions of Change Coalition Health group, sits on SBE Life Sciences Council and ARCS Signature Program Advisory Board, and serves as an Ambassador for Rotary Oceania Medical Aid for Children (ROMAC).

Previously, Gavin was Managing Director Australia/NZ and Vice President Asia Pacific for Johnson & Johnson Medical Devices, Chair of the Medical Technology Association of Australia, Governor of American Chamber of Commerce, Co-Founder/Chair of Macquarie Park Business Coalition (in partnership with United Way) and Australian Co-Chair of the Health Technology Sector Group of the Australia/NZ Leadership Forum.

Gavin is a Graduate of the Australian Institute of Company Directors.

As a co-inventor on a patented and ASX listed digital health technology; Grace Lethlean has been actively involved in the development of health technologies from invention, through clinical trials, to commercialisation.

Grace is co-founder and Chief Product Officer of ANDHealth, Australia’s national digital health initiative, accelerating the commercialisation of evidence-based digital health technologies. Grace’s focus is on supporting digital health technologies to meet key investor, partner and customer requirements around clinical and commercial validation.

Grace also supports the sector through numerous state and national Advisory Panels and Committees, is a 2020 SuperStar of STEM, is an inventor on patents in the US and Australia, a published author on digital health commercialisation, a 2022 Churchill Fellow, investigating international best practice in digital health business support and recognised in 2024 as an AFR Women in Leadership.